Advanced in Inclusion Body Myopathy 2

Dr. Heather A. Lau

Pediatric Neurology | Neurology
240 E 38th St, 20th Floor, 
New York, NY 
Advanced in Inclusion Body Myopathy 2
240 E 38th St, 20th Floor, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Heather Lau is a Pediatric Neurologist and a Neurologist in New York, New York. Dr. Lau is rated as an Advanced provider by MediFind in the treatment of Inclusion Body Myopathy 2. Her top areas of expertise are Gaucher Disease, Sandhoff Disease, Gaucher Disease Type 2, and Gaucher Disease Type 3.

Her clinical research consists of co-authoring 36 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Inclusion Body Myopathy 2.

Specialties
Pediatric Neurology
Neurology
Licenses
Neurology with Special Qualifications in Neurology in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

240 E 38th St, 20th Floor, New York, NY 10016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: SHP611
Study Phase: Phase 2
A Combination Retrospective Medical History and Prospective Observational Study of Patients With Canavan Disease for Assessment of Natural History of Canavan Disease
A Combination Retrospective Medical History and Prospective Observational Study of Patients With Canavan Disease for Assessment of Natural History of Canavan Disease
Enrollment Status: Active_not_recruiting
Publish Date: June 22, 2025
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Biological
Study Drug: ST-920
Study Phase: Phase 1/Phase 2
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Enrollment Status: Terminated
Publish Date: December 30, 2024
Intervention Type: Drug
Study Drug: Venglustat GZ402671
Study Phase: Phase 3
Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the US
Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the US
Enrollment Status: Available
Publish Date: August 16, 2024
Intervention Type: Drug
Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study
Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: IB1001
Study Phase: Phase 2
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)
Enrollment Status: Terminated
Publish Date: January 26, 2023
Intervention Type: Biological
Study Drug: SB-318
Study Phase: Phase 1/Phase 2
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
Enrollment Status: Terminated
Publish Date: October 25, 2022
Intervention Type: Biological
Study Drug: SB-913
Study Phase: Phase 1/Phase 2
An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease
An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease
Enrollment Status: Completed
Publish Date: February 01, 2022
Intervention Type: Dietary supplement, Drug
Study Phase: Phase 4
MPS VI Clinical Surveillance Program (CSP)
MPS VI Clinical Surveillance Program (CSP)
Enrollment Status: Completed
Publish Date: April 05, 2021
Prevalence of Gaucher Among Patients With Osteopenia/Osteoporosis
Prevalence of Gaucher Among Patients With Osteopenia/Osteoporosis
Enrollment Status: Completed
Publish Date: March 23, 2021
Intervention Type: Other
A Natural History Study of Canavan Disease: MGH Site
A Natural History Study of Canavan Disease: MGH Site
Enrollment Status: Completed
Publish Date: November 01, 2019
Longitudinal Studies of Brain Structure and Function in MPS Disorders
Longitudinal Studies of Brain Structure and Function in MPS Disorders
Enrollment Status: Completed
Publish Date: September 06, 2019
View 14 Less Clinical Trials

36 Total Publications

Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses.
Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses.
Journal: Molecular genetics and metabolism
Published: June 25, 2024
Similar Doctors
Advanced in Inclusion Body Myopathy 2
Dr. Florence Shum
Neurology
Advanced in Inclusion Body Myopathy 2
Dr. Florence Shum
Neurology

NY Neurocare Medical Services PLLC

8321 20th Ave, 
Brooklyn, NY 
 (9.8 miles away)
718-996-9888
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Florence Shum is a Neurologist in Brooklyn, New York. Dr. Shum is rated as a Distinguished provider by MediFind in the treatment of Inclusion Body Myopathy 2. Her top areas of expertise are Corpus Callosum Dysgenesis Hypopituitarism, Subependymal Nodular Heterotopia, Lhermitte-Duclos Disease, and Focal or Multifocal Malformations in Neuronal Migration.

Advanced in Inclusion Body Myopathy 2
Dr. John T. Hughes
Neurology
Advanced in Inclusion Body Myopathy 2
Dr. John T. Hughes
Neurology

John T. Hughes, M.D.

275 North Street, 
Newburgh, NY 
 (54.9 miles away)
845-391-8850
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Hughes is a Neurologist in Newburgh, New York. Dr. Hughes has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Inclusion Body Myopathy 2. His top areas of expertise are Peripheral Neuropathy, Autosomal Dominant Partial Epilepsy with Auditory Features, Benign Paroxysmal Positional Vertigo, and Essential Tremor. Dr. Hughes is currently accepting new patients.

Advanced in Inclusion Body Myopathy 2
Dr. Mikhail Charny
Neurology
Advanced in Inclusion Body Myopathy 2
Dr. Mikhail Charny
Neurology
2647 Coney Island Ave, 
Brooklyn, NY 
 (10.7 miles away)
718-336-2166
Languages Spoken:
English
See accepted insurances

Mikhail Charny is a Neurologist in Brooklyn, New York. Dr. Charny is rated as an Experienced provider by MediFind in the treatment of Inclusion Body Myopathy 2. His top areas of expertise are Myofibrillar Myopathy, Cytoplasmic Body Myopathy, Inclusion Body Myopathy 2, and Wieacker Wolff Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lau's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile